Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
57.14 USD | +1.30% | +3.20% | -8.40% |
Apr. 18 | Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating | MT |
Apr. 17 | Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.40% | 4.79B | |
+4.60% | 43.43B | |
+47.58% | 41.69B | |
+10.50% | 41.31B | |
-10.82% | 27.14B | |
+9.72% | 25.28B | |
-24.42% | 18.47B | |
+34.99% | 12.59B | |
+2.43% | 12.33B | |
+8.35% | 11.03B |
- Stock Market
- Equities
- CRSP Stock
- News CRISPR Therapeutics AG
- CRISPR Therapeutics : Jefferies Upgrades CRISPR Therapeutics to Buy from Hold, Lifts PT to $172 From $165